Globeflex Capital L P bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the 2nd quarter, Holdings Channel reports. The fund bought 108,569 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,987,000. ANI Pharmaceuticals comprises 1.1% of Globeflex Capital L P’s holdings, making the stock its 17th largest position.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV bought a new stake in ANI Pharmaceuticals during the first quarter valued at about $28,000. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $28,000. Hantz Financial Services Inc. grew its position in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of ANI Pharmaceuticals in the fourth quarter worth about $48,000. Finally, State of Wyoming bought a new position in shares of ANI Pharmaceuticals in the second quarter worth about $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts recently weighed in on ANIP shares. Guggenheim cut their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Canaccord Genuity Group cut their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.83.
Insider Transactions at ANI Pharmaceuticals
In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares in the company, valued at approximately $5,816,118. This trade represents a 4.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total value of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares in the company, valued at $15,268,698. The trade was a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is currently owned by insiders.
ANI Pharmaceuticals Stock Performance
NASDAQ ANIP opened at $75.35 on Monday. The company’s fifty day moving average is $80.36 and its two-hundred day moving average is $78.88. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 16.24 and a beta of 0.44.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the prior year, the business earned $1.80 earnings per share. The firm’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
